Agoracom

VANCOUVER, British Columbia, Aug 14, 2007 -- ProtoKinetix Inc. (OTCBB: PKTX) announced today that the Company has received from the University of Helsinki, a report confirming a major breakthrough in the storage of stem cells. This emerging and rapidly growing industry generated $12 Billion in revenues in 2005 and is forecasted to exceed $50 Billion in 2010. In this recent report, AAGP(TM) was shown to produce significant increases in stem cell viability and competence under both cryopreservation (-80 degrees C) and at refrigeration (+4 degrees C) temperatures.

This analysis consolidates data from previous findings and observed no conflicting observations. Using cryopreservation on a range of both mouse and human embryonic stem cell lines, there was a consistent increase in the viable yield of almost 100% (from 40% to 76%). Other tests show that 96% of the cells remain in an unaffected state indicating that the stem cells are still competent.

These findings show that AAGP(TM) not only increases cell viability but also maintains cell competence for future use in therapies.

This report and other research data are to be presented to the commercial stem cell storage industry.

About ProtoKinetix:

ProtoKinetix, Inc. is a Biotechnical Company that has developed and patented a family of synthetic anti aging glycoproteins (AAGP(TM)) for human and veterinary medicine, the skin care and cosmetic industries. Using previously published research on native glycoproteins as a guide, and coordinating a vast pool of world recognized bio-molecular research talent in a networked environment, ProtoKinetix is currently negotiating commercial and collaborative agreements on several of the proven and tested applications. Sign up for email news alerts at: www.protokinetix.com

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company's filings with the Securities and Exchange Commission.

Investor Contact:
ProtoKinetix Inc.
Blair Henderson,
604-687-9887